Regulatory FDA Approves Extended Dosing Interval for Regeneron’s EYLEA HD (aflibercept) Big Molecule WatchOn April 2, 2026, Regeneron Pharmaceuticals announced that the U.S.RegulatoryOphthalmologyRead full story pharminent April 15, 2026 Big Molecule Watch On April 2, 2026, Regeneron Pharmaceuticals announced that the U.S. RegulatoryOphthalmologyRead full story Post navigation Previous: Lilly to acquire CrossBridge Bio for up to $300mNext: Travere wins long-awaited approval for kidney disease drug Related Stories Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026 Regulatory HHS appoints permanent FDA CBER, CDER heads pharminent September 10, 2026 Regulatory FDA approves AstraZeneca’s Etcamah combo for advanced breast cancer pharminent September 7, 2026